News

Published on 1 May 2024 on Zacks via Yahoo Finance

Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short

Article preview image

Exelixis, Inc. EXEL reported lower-than-expected results for the first quarter. Its shares fell 7% in after-hours trading following the announcement.EXEL recorded earnings of 17 cents per share, which missed the Zacks Consensus Estimate of 28 cents. The company registered adjusted earnings of 16 cents per share in the first quarter of 2023.

Including stock-based compensation expense, EPS was 12 cents, flat year over year.

Read the rest of the article
NASDAQ.ANIP price evolution
NASDAQ.EXEL price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Exelixis's SWOT analysis: cabozantinib drives growth as stock faces ip...

Exelixis, Inc. (NASDAQ:EXEL), a biotechnology company specializing in the development and...

Investing.com 15 Jan 2025
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and...

Estimates for 2024 loss per share have narrowed to 96 cents from $1.29 in the past 90 days....

Zacks · via Yahoo Finance 15 Jan 2025
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with t...

Zacks · via Yahoo Finance 13 Jan 2025
Exelixis Provides Preliminary 2024 Results and Outlook for 2025

This is the third stock repurchase program undertaken by Exelixis since March 2023. Under this...

Zacks · via Yahoo Finance 13 Jan 2025
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib

Exelixis, Inc. EXEL announced that the FDA has notified it about an update to its supplemental ne...

Zacks · via Yahoo Finance 11 Jan 2025
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?

EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabomety...

Zacks · via Yahoo Finance 7 Jan 2025
Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024?

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we...

Insider Monkey · via Yahoo Finance 23 Dec 2024
Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations

Quote Some better-ranked drugmakers are Novartis NVS, Gilead GILD and Exelixis EXEL, with a Zacks...

Zacks · via Yahoo Finance 18 Dec 2024
Top Research Reports for JPMorgan Chase, UnitedHealth & Verizon

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase...

Zacks · via Yahoo Finance 16 Dec 2024
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Utilizing ratios like P/E, PEG, Price/Sales...Flow, the Value Style Score identifies the most...

Zacks · via Yahoo Finance 25 Nov 2024

Copyright Statfolio @ 2025

Social Accounts